You are here

Two-Year Data Confirm Efficacy of Plegridy (Peginterferon Beta-1a) in MS Patients

Subjects demonstrate improvement in clinical and MRI outcomes

Results from the second year of the phase III ADVANCE trial have shown that the positive treatment effects of Plegridy (peginterferon beta-1a, Biogen idec) were maintained in patients with relapsing multiple sclerosis beyond the first year of the study.

The new findings were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS–ECTRIMS) in Boston.

Post hoc analyses confirmed that the positive effects of Plegridy in reducing disease activity and disability progression were maintained in year 2 of the study. A significantly higher proportion of patients treated with Plegridy during both years of the trial experienced no evidence of disease activity (defined as the absence of clinical and magnetic resonance imaging [MRI] disease activity over 2 years of treatment) compared with those who switched to Plegridy from placebo. Moreover, those treated with Plegridy during both years of the study showed significant reductions in the risk of 24-week confirmed disability progression compared with patients treated with placebo during the first year.

New data from the second year of the ADVANCE trial also showed that patients treated with Plegridy throughout the study experienced statistically significant improvements in clinical and MRI outcomes — including the annualized relapse rate, the risk of relapse, the risk of 24-week confirmed disability progression, and the number of brain lesions — compared with those who switched to Plegridy after taking placebo for the first year. These new data also showed that the safety profile of Plegridy was consistent between years 1 and 2 of the study.

Plegridy is a subcutaneous injectable therapy indicated for relapsing forms of MS. The product consists of interferon beta-1a that has been pegylated to extend its half-life, which allows a less-frequent dosing schedule. Plegridy is a member of the interferon class of treatments for MS.

Source: Biogen Idec; September 11, 2014.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients